Ability of laboratories to detect emerging antimicrobial resistance in nosocomial pathogens: a survey of Project ICARE laboratories
|
|
- Hollie Parker
- 5 years ago
- Views:
Transcription
1 Diagnostic Microbiology and Infectious Disease 38 (2000) Surveillance Ability of laboratories to detect emerging antimicrobial resistance in nosocomial pathogens: a survey of Project ICARE laboratories Christine D. Steward a, *, David Wallace b, Susannah K. Hubert b, Rachel Lawton a, Scott K. Fridkin a, Robert P. Gaynes a, John E. McGowan, Jr b, Fred C. Tenover a a Hospital Infections Program, Centers for Disease Control and Prevention, 1600 Clifton Rd, NE (G08) Atlanta, GA 30333, USA b Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA Abstract A proficiency testing project was conducted among 48 microbiology laboratories participating in Project ICARE (Intensive Care Antimicrobial Resistance Epidemiology). All laboratories correctly identified the Staphylococcus aureus challenge strain as oxacillinresistant and an Enterococcus faecium strain as vancomycin-resistant. Thirty-one (97%) of 32 laboratories correctly reported the Streptococcus pneumoniae strain as erythromycin-resistant. All laboratories testing the Pseudomonas aeruginosa strain against ciprofloxacin or ofloxacin correctly reported the organism as resistant. Of 40 laboratories, 30 (75%) correctly reported resistant MICs or zone sizes for the imipenem- and meropenem-resistant Serratia marcescens. For the extended-spectrum -lactamase (ESBL)-producing strain of Klebsiella pneumoniae, 18 (42%) of 43 laboratories testing ceftazidime correctly reported ceftazidime MICs in the resistant range. These results suggest that current testing generally produces accurate results, although some laboratories have difficulty detecting resistance to carbapenems and extended-spectrum cephalosporins. This highlights the need for monitoring how well susceptibility test systems in clinical laboratories detect emerging resistance Elsevier Science Inc. All rights reserved. 1. Introduction Validation of the ability of clinical laboratories to detect both established and novel resistance patterns is critical for the success of any project involving surveillance of emerging antimicrobial resistance. Proficiency testing is an important part of quality assurance and validates the accuracy of antimicrobial susceptibility data reported by microbiology laboratories (Doern et al., 1999; Rosenberg et al., 1997; Tenover et al., 1999). Validation of susceptibility testing results is particularly important in multicenter studies where multiple techniques are used for testing. When proficiency testing indicates that laboratories within the system or network are achieving comparable susceptibility test results, comparisons of resistance rates among institutions become more meaningful. In addition, each laboratory then can compare its results with aggregated results from all other participating laboratories (benchmarking) (Jones et al., 1997a; Pfaller et al., 1999; Steward et al., 1998). Here we present the results from a proficiency testing project undertaken in hospitals participating in Project ICARE (Intensive Care Antimicrobial Resistance Epidemiology). Project ICARE conducts laboratory-based surveillance for antimicrobial resistance and antimicrobial use at U.S. hospitals participating in the National Nosocomial Infections Surveillance System (NNIS) (Archibald et al., 1997; Fridkin et al., 1999). Proficiency testing was one of the tools employed to validate monthly, aggregated antimicrobial susceptibility testing results sent to the Project ICARE master dataset by the hospitals. 2. Materials and methods 2.1. ICARE hospitals * Corresponding author. Tel.: ; fax: address: cks7@cdc.gov (C.D. Steward). Current address. Bacterial and Mycotic Diseases (D63). Centers for Disease Control and Prevention Clifton Road, NE. (G08), Atlanta, GA In March 1998, 48 microbiology laboratories within the United States participated in the Project ICARE proficiency testing program. The laboratories were located in 26 states in the following regions: Northeast (7 states, 18 laborato /00/$ see front matter 2000 Elsevier Science Inc. All rights reserved. PII: S (00)
2 60 C.D. Steward et al. / Diagnostic Microbiology and Infectious Disease 38 (2000) ries), South (10 states, 18 laboratories), Midwest (6 states, 8 laboratories), and West (3 states, 4 laboratories) Proficiency testing organisms The Hospital Infections Program at the Centers for Disease Control and Prevention (CDC) sent the following six challenge isolates to participating laboratories: a homogeneous oxacillin-resistant Staphylococcus aureus, a vancomycin-resistant Enterococcus faecium (NJ1) (Tenover et al., 1993), an erythromycin-resistant Streptococcus pneumoniae with reduced susceptibility to penicillin, a ciprofloxacinand ofloxacin-resistant Pseudomonas aeruginosa, an imipenem- and meropenem-resistant Serratia marcescens (Yigit et al., 1999), and Klebsiella pneumoniae ATCC , which is an extended-spectrum -lactamase (ESBL) producer. Each organism was selected from the CDC culture collection based on its resistance phenotype and genotype. The genotypes of the S. aureus (meca), E. faecium (vana), and K. pneumoniae (bla SHV-18 ) were confirmed by using specific polymerase chain reaction (PCR) assays (Clark et al., 1993; Mabilat & Goussard, 1993; Rasheed et al., 1997; Vannuffel et al., 1995). The P. aeruginosa strain was shown to maintain ciprofloxacin resistance after ten passages on nonselective trypticase soy agar plates containing 5% sheep blood (blood agar plates) (BD 1, Sparks, MD). The S. marcescens contained a bla SME-1 -like carbapenemase and outer membrane porin changes, producing high-level resistance to imipenem and meropenem (Yigit et al., 1999). The S. marcescens continued to be imipenem-resistant after eight passages on non-selective blood agar plates Isolate preparation 1 Use of trade names is for identification purposes only and does not constitute endorsement by the Public Health Service or the U.S. Department of Health and Human Services In preparation for shipment, the isolates were transferred to blood agar plates from storage in defibrinated sheep blood (Lampire Biologic Laboratories, Pipersville, PA) at 70 C. After a 24 h incubation, the plates were inspected for purity, and colonies were inoculated into 49 sets of nutrient agar stabs (one set for each ICARE laboratory and the CDC laboratory). The S. pneumoniae challenge strain was inoculated onto slants containing trypticase soy agar with 5% sheep blood (BD). The stabs and slants were incubated at 35 C overnight. After incubation, the stabs and slants were examined for growth and one set of organisms was sent to each of the 48 ICARE laboratories via overnight delivery. The CDC set was left at room temperature overnight. The proficiency testing protocol required that each organism be transferred to a blood agar plate and incubated at 35 C overnight upon arrival at the ICARE laboratories. One additional transfer was required before testing was performed. In the same manner, the organisms were transferred to blood agar plates twice in the CDC laboratory before testing Isolate testing Laboratories performed routine antimicrobial susceptibility testing on all organisms and routine identification to species level on the E. faecium and K. pneumoniae (identified in the instructions to the laboratory directors only as Enterococcus species and Gram-negative bacillus). Susceptibility test systems used by the ICARE laboratories included Vitek (biomérieux, Inc., Hazelwood, MO), MicroScan (Dade Behring, Inc., West Sacramento, CA), disk diffusion, Sensititre (Trek Diagnostics, Westlake, OH), and Etest (AB BIODISK North America, Inc., Piscataway, NJ). The oxacillin disk test was used by some hospitals to screen the S. pneumoniae strain for potential penicillin resistance (National Committee for Clinical Laboratory Standards, 1997a; National Committee for Clinical Laboratory Standards, 1998). As the study referee, CDC tested all isolates using broth microdilution plates made in-house, according to National Committee for Clinical Laboratory Standards (NCCLS) guidelines (National Committee for Clinical Laboratory Standards, 1997b). Quality control for broth microdilution was performed using the following organisms: S. aureus ATCC 29213, S. aureus ATCC 43300, S. aureus ATCC 43387, E. coli ATCC 25922, P. aeruginosa ATCC 27853, E. faecalis ATCC 29212, E. faecalis ATCC 51299, and S. pneumoniae ATCC For identification of the E. faecium to species level, laboratories used Vitek cards, MicroScan panels, API 20 Strep strips (biomérieux, Inc.), Minitek disks (BD), and RapID STR (Innova Diagnostics, San Diego, CA). For identification of the K. pneumoniae to species level, laboratories used Vitek cards, MicroScan panels, Sensititre panels, and API 20E strips (biomérieux, Inc.). The CDC laboratory used reference biochemical tests to identify each isolate to species level (Facklam et al., 1999; Farmer et al., 1980; Farmer, 1999). The quantitative results (minimum inhibitory concentration [MIC] and disk diffusion values) and the categorical interpretations (susceptible, intermediate, and resistant) were transcribed by each laboratory to worksheets supplied by the Project ICARE laboratory. The worksheets, which contained a list of preprinted antimicrobial agent names and spaces for additional agents, also included spaces for test date, test method, identification, and identification method, where appropriate. On the worksheet for the S. pneumoniae challenge strain, space was provided only for MICs of penicillin, cefotaxime, and ceftriaxone. At the bottom of each worksheet, the laboratory was invited to list any comments about the susceptibility profile that would be reported to the patient s chart. The worksheets from each laboratory were sent to the Project ICARE laboratory for analysis.
3 C.D. Steward et al. / Diagnostic Microbiology and Infectious Disease 38 (2000) Data analysis Results for each specific antimicrobial agent were analyzed separately. Testing errors were determined by comparing CDC broth microdilution MICs and categorical interpretations based on NCCLS criteria (National Committee for Clinical Laboratory Standards, 1998) with the results from the participating laboratories. Acceptable results were MICs within 1 dilution from the reference result or test interpretations (e.g., susceptible, intermediate, or resistant) resulting in no error or a minor error when compared to the reference interpretation. Minor errors occurred when the test result or reference result was intermediate and the other result was susceptible or resistant. MIC results outside 1 dilution, major errors (test result resistant and reference result susceptible), and very major errors (test result susceptible and reference result resistant) were considered incorrect results. Disk diffusion errors were based on categorical interpretations. For the antimicrobial agents studied, no categorical interpretation changes occurred in NCCLS guidelines between 1998 and 1999 (National Committee for Clinical Laboratory Standards, 1998; National Committee for Clinical Laboratory Standards, 1999) Supplemental information In February 1998, before the initiation of the proficiency testing program, all laboratories filled out a survey describing their microbiology methods. This survey included detailed information on the antimicrobial susceptibility methods used to test bacteria. If the susceptibility test method was automated, laboratories recorded the specific panel or card types used for testing. The panel and card type information was extracted and used as supplemental information in the proficiency testing analysis. In March 1998, along with testing of the isolates, each laboratory was asked to record the last ten MIC or disk diffusion zone sizes measured for the control strain, E. coli ATCC These quality assurance data were used to supplement the proficiency testing analysis, specifically for imipenem and ceftazidime. In a follow-up study conducted in February 1999, a subset of Vitek users were sent the imipenem- and meropenem-resistant S. marcescens strain that was previously sent for proficiency testing in March The five Vitek users who participated had reported the strain as imipenemsusceptible, -intermediate, or -resistant in the proficiency testing. In the follow-up study, the isolate was tested in the same manner as described for the previous proficiency testing challenge. Results of the 1999 follow-up study were compared with those from the 1998 proficiency testing report. 3. Results Of the 48 laboratories participating in the Project ICARE proficiency testing program, 21 (44%) reported correct results for all 27 organism-antimicrobial agent combinations analyzed. Of the 27 laboratories producing errors, 20 (74%) produced only one error, five (18%) produced two errors, one (4%) produced three errors, and one laboratory (4%) produced four errors among the 27 organism-antimicrobial agent combinations analyzed. Detailed analysis of the errors is shown below Oxacillin/methicillin-resistant S. aureus (MRSA) All 48 laboratories correctly reported the isolate as oxacillin- and penicillin-resistant. Oxacillin and penicillin reference MICs were 16 g/ml and 2 g/ml, respectively. Of the 45 laboratories that tested the isolate against erythromycin, all 45 correctly reported the organism as erythromycin-resistant (reference MIC 8 g/ml). Most laboratories used Vitek cards (26 laboratories) or MicroScan conventional panels (16 laboratories) for susceptibility testing. Other methods included disk diffusion (three laboratories), MicroScan Auto or Touchscan panels (two laboratories), or MicroScan rapid panels (one laboratory) Vancomycin-resistant E. faecium Forty-three (90%) of 48 laboratories correctly identified the enterococcal challenge organism as an E. faecium. One laboratory incorrectly reported the organism as an E. durans. Four laboratories (two Vitek users and two disk diffusion users) reported that they do not identify enterococci to species level. Of the 44 laboratories that identified the organism to species level, 34 used the same system for identification and vancomycin susceptibility testing (21 Vitek users and 13 MicroScan users). The other 10 laboratories used different methods for identification, including Sensititre, Minitek, RapID STR, and API 20 STREP. All laboratories correctly reported the organism as vancomycin-resistant (reference MIC g/ml) (Table 1). Forty-five (98%) of 46 laboratories correctly reported ampicillin-susceptible MICs or zone sizes (reference MIC 4 8 g/ml). One Vitek user incorrectly reported a resistant ampicillin MIC of 16 g/ml (Table 1). One MicroScan user correctly reported an ampicillin MIC of 4 g/ml (susceptible), but incorrectly interpreted the MIC as intermediate. Thirty-nine (98%) of 40 laboratories correctly reported the organism as penicillin-resistant (reference MIC 32 g/ ml). One Vitek user incorrectly reported a susceptible penicillin MIC of 8 g/ml (Table 1).
4 62 C.D. Steward et al. / Diagnostic Microbiology and Infectious Disease 38 (2000) Table 1 E. faecium: Results by Test Method Antimicrobial Agent (n a ) Laboratory Test Method MicroScan b Vitek b Disk Rapid Conventional Auto or diffusion b Touchscan Etest b Vancomycin (48) key result - 16/16 2/2 23/23 4/4 3/3 Ampicillin (46) - 16/16 1/1 23/24 3/3 2/2 Penicillin (40) 1/1 14/14 2/2 20/21 1/1 1/1 b Number of correct MICs or disk diffusion results/total number of laboratories reporting a result for the antimicrobial agent Erythromycin-resistant S. pneumoniae with reduced susceptibility to penicillin Thirty-one (97%) of 32 laboratories testing erythromycin correctly reported the pneumococcal challenge strain as resistant (Table 2). One laboratory incorrectly reported an erythromycin zone size of 26 mm (susceptible). The other 18 disk diffusion users correctly reported a resistant erythromycin zone size. The S. pneumoniae produced a reference oxacillin disk test zone size of 15 mm, indicating that penicillin MICs should be performed to confirm penicillin resistance. Penicillin reference MICs for this organism were 0.03 to 0.12 g/ml (susceptible to intermediate). [According to NCCLS criteria, penicillin MICs of 0.06 are susceptible, and MICs of g/ml are intermediate (National Committee for Clinical Laboratory Standards 1998).] In this survey, 24 laboratories performed an oxacillin disk test and a penicillin MIC, 18 laboratories performed a penicillin MIC only, four laboratories performed an oxacillin disk test and noted that a referral laboratory would perform an MIC, and two laboratories performed the oxacillin disk test and did not report a subsequent penicillin result. All 30 laboratories performing an oxacillin disk test correctly reported oxacillin disk screen results of 19 mm (range: 6 19 mm). No laboratories reported testing penicillin by disk diffusion. Forty-two laboratories (35 Etest users and seven MicroScan MicroStrep panel users) reported penicillin MICs. Forty laboratories reported penicillin MICs of g/ml. Two laboratories, both Etest users, reported intermediate MICs of 0.64 g/ml, an MIC not found on the penicillin Etest strip. Four laboratories reported penicillin Etest results of g/ml and interpreted the MIC incorrectly as intermediate. One laboratory reported an MIC of g/ml and interpreted the MIC incorrectly as susceptible. All laboratories reporting cefotaxime and/or ceftriaxone results used MicroScan MicroStrep panels (seven laboratories) or Etest (17 laboratories) and correctly reported those drugs as susceptible. No laboratories reported disk diffusion testing of cephalosporins Ciprofloxacin- and ofloxacin-resistant P. aeruginosa Forty-seven laboratories correctly reported the P. aeruginosa isolate as resistant to ciprofloxacin (46 laboratories; reference MIC 8 g/ml), ofloxacin (22 laboratories; reference MIC 8 g/ml), or both drugs. One laboratory did not report results for any fluoroquinolones. For other antimicrobial agents, all laboratories correctly reported the organism as ceftazidime-susceptible (reference MIC 2 g/ ml), and laboratories reporting either imipenem (43 laboratories), meropenem (two laboratories), or both drugs correctly reported the organism as carbapenem-susceptible. The imipenem and meropenem reference MICs were 1 2 g/ml and 0.25 g/ml, respectively. The most commonly used susceptibility testing methods for the P. aeruginosa were Vitek cards and MicroScan Table 2 S. pneumoniae: Test Results Antimicrobial Agent (n a ) Reference Laboratory Broth Microdilution MIC Results b Pooled Results by Category c Susceptible Intermediate Resistant Erythromycin (32) key result 8 g/ml (R) 1-31 Penicillin (42) g/ml (S or I) Cefotaxime (24) g/ml (S) Ceftriaxone (20) g/ml (S) b R, resistant; I, intermediate; S, susceptible. c Based on reported MIC or zone size.
5 C.D. Steward et al. / Diagnostic Microbiology and Infectious Disease 38 (2000) Table 3 P. aeruginosa: Results by Test Method Antimicrobial Agent (n a ) Laboratory Test Method MicroScan b Vitek b Disk Rapid Conventional Auto or Touchscan Diffusion b Ciprofloxacin (46) - 16/16 2/2 22/22 6/6 key result Ofloxacin (22) - 10/10-9/9 3/3 key result Ceftazidime (48) - 16/16 2/2 24/24 6/6 Imipenem (43) - 15/15 2/2 21/21 5/5 Meropenem (2) - 1/ /1 b Number of correct MICs or disk diffusion results/total number of laboratories reporting a result for the antimicrobial agent. conventional panels (Table 3). No laboratories used MicroScan rapid panels for P. aeruginosa testing Imipenem- and meropenem-resistant S. marcescens Thirty-nine of 48 laboratories reported results for imipenem, and one laboratory reported results for both imipenem and meropenem for the S. marcescens challenge strain. Of the 40 laboratories reporting imipenem results, 30 (75%) correctly reported an imipenem MIC of 16 g/ml (resistant) (Table 4). One laboratory reported the organism correctly as imipenem resistant (MIC 8 g/ml) but incorrectly as meropenem susceptible (MIC 4 g/ml). To test imipenem, 21 laboratories used Vitek cards, 14 used MicroScan conventional panels, two used MicroScan Auto or Touchscan panels, two used disk diffusion, and one used MicroScan rapid panels. Of the six laboratories incorrectly reporting imipenem-susceptible MICs or zone sizes, one used disk diffusion (zone size reported as 16 mm) and five used Vitek (MICs reported as 4 g/ml). Imipenemintermediate MICs were reported by three Vitek users and one MicroScan rapid panel user. Of the eight Vitek users incorrectly reporting imipenem-susceptible or -intermediate MICs, six different Vitek cards were used for testing, and five of the six card types were the same as card types used in laboratories that correctly reported resistant imipenem MICs for this organism. Eight of the ten laboratories incorrectly reporting imipenem-susceptible or -intermediate MICs or zone sizes had quality control results for E. coli ATCC that were within the acceptable range for imipenem (MICs, g/ml, and disk diffusion zone sizes, mm) (National Committee for Clinical Laboratory Standards 1998). Two of the ten laboratories did not report imipenem quality control data. When the February 1999 test results of the S. marcescens challenge strain were compared to the original proficiency test results, three of the five Vitek users reported the same results both times. In both studies, two of the five Vitek users correctly reported an imipenem MIC of 16 g/ml (resistant), and one incorrectly reported an imipenem MIC of 8 g/ml (intermediate). The other two laboratories reported results of 4 g/ml (susceptible) to 8 g/ml in the 1998 proficiency testing study and 8 g/ml to 16 g/ml in the 1999 follow-up study. For ceftazidime, 37 (90%) of 41 laboratories correctly reported the organism as susceptible (Table 4). All four laboratories reporting incorrect (intermediate or resistant) results were MicroScan users. One laboratory reported a ceftazidime MIC of 16 g/ml (intermediate), and three other laboratories reported ceftazidime MICs of 16 g/ml (resistant). The four MicroScan users incorrectly reporting ceftazidime-intermediate or -resistant MICs used four different MicroScan panels for testing. All four panel types were the same as panel types used in laboratories correctly reporting the organism as ceftazidime-susceptible. All laboratories correctly reported ciprofloxacin, ofloxacin, or both as susceptible (Table 4) ESBL-producing K. pneumoniae ATCC All 48 laboratories correctly identified this organism as K. pneumoniae. Forty-four laboratories used the same system for organism identification and susceptibility testing (25 Vitek; 19 MicroScan). Four laboratories reported disk diffusion results for at least one drug. Two of these laboratories Table 4 S. marcescens: Test Results Antimicrobial agent (n a ) Reference Laboratory Broth Microdilution MIC Results b Pooled Results by Category c Susceptible Intermediate Resistant Imipenem (40) key result 32 g/ml (R) Meropenem (1) key result g/ml (R) Ceftazidime (41) 2 g/ml (S) Ciprofloxacin (46) g/ml (S) Ofloxacin (27) g/ml (S) b R, resistant; I, intermediate; S, susceptible. c Based on reported MIC or zone size.
6 64 C.D. Steward et al. / Diagnostic Microbiology and Infectious Disease 38 (2000) Table 5 K. pneumoniae: Test Results Antimicrobial Agent (n a ) Reference Laboratory Broth Microdilution MIC Results b Pooled Results by Category c Susceptible Intermediate Resistant Extended-spectrum cephalosporin Ceftazidime (43) g/ml (R-R) Cefotaxime (32) 4 16 g/ml (S-I) Ceftriaxone (37) 8 16 g/ml (S-I) Monobactam Aztreonam (16) g/ml (R-R) Cephamycin Cefotetan (16) g/ml (S) Cefoxitin (20) g/ml (R) Cephalosporin Cefazolin or Cephalothin (48) 32 g/ml (R) b R, resistant; I, intermediate; S, susceptible. c Based on reported MIC or zone size. identified organisms using an API 20E strip, another used a Sensititre panel, and the other used a Vitek card. The laboratories reported a wide spectrum of MICs and zone sizes for testing of cephalosporins and cefoxitin against this organism (Table 5). Forty-three (90%) of the 48 laboratories tested ceftazidime (23 Vitek users, 15 MicroScan conventional panel users, two MicroScan Auto or Touchscan users, two disk diffusion users, and one MicroScan rapid panel user). Eight laboratories, all Vitek users, reported incorrect MICs of 8 g/ml. However, two of the eight laboratories identified the organism as an ESBLproducer and changed the ceftazidime results to resistant, as recommended by NCCLS standard M100-S9 (National Committee for Clinical Laboratory Standards, 1999). Seven of the eight laboratories used Vitek card types that also were used by other laboratories that reported intermediate ceftazidime MICs. The ceftazidime quality control data for E. coli ATCC for seven of the eight laboratories were within the acceptable range for ceftazidime (MICs, g/ml) (National Committee for Clinical Laboratory Standards 1998). One laboratory did not report ceftazidime quality control data. Results for several other cephems were reported incorrectly. Three laboratories, using three different MicroScan conventional panels, incorrectly reported MICs of 32 g/ml for cefotaxime or ceftriaxone or both, while 12 MicroScan conventional panel users correctly reported susceptible or intermediate MICs. Two of the three panel types used by laboratories incorrectly reporting cefotaxime or ceftriaxone MICs were also used by laboratories correctly reporting susceptible or intermediate MICs. For cefoxitin, five laboratories, all Vitek users, reported an incorrect susceptible MIC of 8 g/ml, while eight Vitek users correctly reported intermediate or resistant cefoxitin MICs. Two of the three card types used by laboratories incorrectly reporting susceptible cefoxitin MICs were used by laboratories correctly reporting intermediate or resistant cefoxitin MICs. For cefazolin, one laboratory, a Vitek user, reported an incorrect intermediate MIC of 16 g/ml. All laboratories reported results for at least one extended-spectrum cephalosporin (ceftazidime, cefotaxime, or ceftriaxone). For the three extended-spectrum cephalosporins and aztreonam, 12 laboratories reported results for all four drugs, 25 reported results for three drugs, nine reported results for two drugs, and two reported results for a single drug (i.e., cefotaxime). By reported categorical interpretation, 35%, 47%, and 35% of Vitek users and 100%, 33%, and 29% of MicroScan conventional panel users reported the K. pneumoniae resistant to ceftazidime, cefotaxime, and ceftriaxone, respectively. Nine laboratories reported the organism as an ESBLproducer but did not change extended-spectrum cephalosporin and aztreonam MIC or zone size interpretations to resistant as suggested by NCCLS for ESBL-producing organisms (National Committee for Clinical Laboratory Standards, 1998). Eleven laboratories reported at least one susceptible or intermediate MIC and changed the extendedspectrum cephalosporin and aztreonam interpretation to resistant. Seven of the 11 laboratories reported the organism as an ESBL-producer. 4. Discussion The ability of clinical laboratories to detect antimicrobial resistance is critical in this era of emerging infectious diseases. This study suggests that current testing in clinical microbiology laboratories generally produces accurate results, although some resistant phenotypes are difficult to detect. Twenty-one laboratories correctly reported all 27 organism-antimicrobial agent combinations analyzed, and twenty laboratories missed only one result. Of the key results, the Project ICARE laboratories had little trouble
7 C.D. Steward et al. / Diagnostic Microbiology and Infectious Disease 38 (2000) detecting homogeneous oxacillin resistance in S. aureus (which several other laboratories had failed to detect as oxacillin resistant in previous proficiency testing challenges), high-level vancomycin resistance in E. faecium, and high-level fluoroquinolone resistance in P. aeruginosa. Errors occurred predominantly in carbapenem and extendedspectrum cephalosporin testing. In this study, ten laboratories had difficulty detecting high-level imipenem resistance in the S. marcescens isolate. The results for imipenem from the eight laboratories reporting quality control data were within the acceptable range. While it is known that imipenem testing is difficult due to a variety of factors, most studies have focused on false imipenem resistance due to imipenem degradation in the test panels (Carmeli et al., 1998; Grist, 1992; O Rourke et al., 1991; White et al., 1991) and problems with automated instrument susceptibility test interpretations (Biedenbach & Jones, 1995; Jones et al., 1997b). In our study, the Gramnegative bacilli that were susceptible to imipenem, P. aeruginosa and K. pneumoniae, were tested as susceptible by all laboratories reporting imipenem for those organisms. One possible reason for under-reporting of imipenem resistance in the challenge strain of S. marcescens was that a particular test method could not accurately detect carbapenem resistance. Ten laboratories using three different methods incorrectly reported the organism as susceptible or intermediate to imipenem. However, each method was also used by at least one other laboratory that reported the organism as imipenem-resistant. Even though eight of the ten laboratories reporting incorrect results were Vitek users, no one particular card type was associated with underreporting of imipenem. Therefore, one method or card type was not likely the cause of the under-reporting. To further investigate under-reporting, the isolate of S. marcescens was sent again to five Vitek users in February Reasons for the changes in MICs between the 1998 proficiency testing and 1999 follow-up study are unclear but may be related to heightened awareness of the problems of imipenem testing. Project ICARE hospitals were informed about potential imipenem testing problems through proficiency testing feedback and validation study results (Steward et al., 1998). Another reason for some of the under-reporting of imipenem resistance in the S. marcescens strain could be due to the isolate itself. Carbapenem resistance in this isolate is due to a combination of carbapenemase production and porin changes. Thus, subpopulations that have either lost the bla SME-1 -like carbapenemase or have reduced expression of the enzyme could produce carbapenem-intermediate results. Furthermore, the porin changes could revert, causing the organism to test as carbapenem-susceptible if the carbapenemase was also lost. Ceftazidime errors included reports of both false resistance and false susceptibility. Four MicroScan users incorrectly reported ceftazidime intermediate or resistant MICs for the S. marcescens, while eight Vitek users incorrectly reported the K. pneumoniae as ceftazidime-susceptible. Reasons for the inaccurate reporting of ceftazidime results are unclear. As with imipenem, the quality control results for each hospital were reviewed and all reported results were within range. The cards and panels that were used in one laboratory providing incorrect results were used in other laboratories that provided correct results. However, four of the six Vitek users that incorrectly reported the S. marcescens as imipenem-susceptible also incorrectly reported the K. pneumoniae as ceftazidime- susceptible or cefoxitinsusceptible, which suggests that these cards may have been under-inoculated. The K. pneumoniae isolate sent for proficiency testing was an ESBL-producer. In 1998, at the time of this proficiency testing, NCCLS recommended screening for ESBL production in isolates of K. pneumoniae, K. oxytoca, and E. coli using unique breakpoints of 2 g/ml for cefpodoxime, ceftazidime, or aztreonam (National Committee for Clinical Laboratory Standards, 1998). In addition, these guidelines suggested that cephalosporins and aztreonam should be reported as resistant by stating that strains of Klebsiella spp. and E. coli may be clinically resistant to cephalosporin and aztreonam therapy by virtue of extendedspectrum production, despite apparent in vitro susceptibility to some of these agents (National Committee for Clinical Laboratory Standards, 1998). The 1999 NCCLS guidelines provide more detailed information about screening and confirming ESBL-producing organisms, including the recommendation to use more than one agent for screening (National Committee for Clinical Laboratory Standards, 1999). In addition, the new guidelines recommend that all ESBLproducing strains be reported as resistant for all penicillins, cephalosporins, and aztreonam, despite in vitro test results. From the proficiency testing results, it is clear that confusion regarding ESBL identification and reporting was not uncommon at the time of this project. A wide variety of combinations of extended-spectrum cephalosporins and aztreonam was tested. Only 11 of 48 laboratories changed the extended-spectrum cephalosporin and aztreonam MIC or zone size interpretations to resistant as suggested by NCCLS for ESBL-producing organisms (National Committee for Clinical Laboratory Standards, 1998). Of these 11, seven reported the organism as an ESBL-producer. Nine other laboratories also reported the strain as an ESBL-producer even though they did not modify all extended-spectrum cephalosporin and aztreonam results to be resistant. The remaining 28 laboratories did not report the organism as an ESBL-producer and did not modify drug interpretations to reflect ESBL status. More specific NCCLS guidelines on ESBL detection have been published since this proficiency testing program was performed (National Committee for Clinical Laboratory Standards, 1999). Problems associated with testing VRE were first reported in 1993 (Tenover et al., 1993), and difficulties still are apparent. One laboratory identified the E. faecium as an E. durans and reported a vancomycin disk diffusion zone size
8 66 C.D. Steward et al. / Diagnostic Microbiology and Infectious Disease 38 (2000) of 6 mm (resistant). Although vancomycin-resistant E. durans have been reported (Cercenado et al., 1996), this identification is uncommon and has been confused with E. faecium (Singer et al., 1996). Thus, potential E. durans should be confirmed biochemically (Facklam et al., 1999). Most clinical enterococcal isolates that are vancomycinresistant are E. faecium or E. faecalis (Clark et al., 1993). In our study, one laboratory misinterpreted an E. faecium ampicillin MIC result of 4 g/ml, which is susceptible, as intermediate; however, there is no intermediate breakpoint for ampicillin for enterococci (National Committee for Clinical Laboratory Standards, 1998). For the S. pneumoniae challenge strain, two laboratories reported an oxacillin disk test result of 19 mm but failed to report a penicillin MIC result. According to NCCLS guidelines, organisms producing zone sizes of 19 mm should be further tested using a penicillin MIC method to confirm resistance (National Committee for Clinical Laboratory Standards, 1998). Another laboratory misinterpreted an Etest penicillin MIC result of g/ml (which should be rounded up to 0.1 g/ml) as susceptible, and four laboratories misinterpreted an MIC of g/ml (susceptible) as intermediate. The misinterpretations may have stemmed from rounding errors. The value of g/ml may have been rounded down to meet the susceptible breakpoint of 0.06 g/ml, while the value of g/ml most likely was rounded up to meet the intermediate breakpoints of g/ml. MIC values should only be rounded up for Etest values that fall between two-fold dilutions (e.g., a result of 3 g/ml is rounded to 4 g/ml) (AB BIODISK North America Inc., 1997). In addition, NCCLS uses only 2 decimal places for MIC values and thus g/ml should be considered susceptible. In general, Project ICARE laboratories performed well. The susceptibility testing errors that occurred with imipenem and extended-spectrum cephalosporin testing most likely are a result of the particular organisms tested, the susceptibility test systems themselves, and the way that an individual test was performed. This study highlights the need for monitoring how well susceptibility test systems detect emerging resistance and the need for more education about detecting and reporting emerging resistance in clinical laboratories. Acknowledgments We thank Hesna Yigit, Kamile Rasheed, and Jana Swenson for helpful discussions. We thank the microbiology personnel at Project ICARE hospitals for testing the organisms and providing results. Phase 3 of Project ICARE was supported in part by grants to the Rollins School of Public Health of Emory University by Astra-Zeneca Pharmaceuticals, Wilmington, DE (full sponsor); Pfizer, Incorporated, New York, NY (full sponsor); Roche Laboratories, Nutley, NJ (full sponsor); American Society for Health-System Pharmacists Research and Education Foundation, Bethesda, MD; Bayer Corporation, Pharmaceuticals Division, West Haven, CT; Kimberly Clark Corporation, Roswell, GA; National Foundation for Infectious Diseases, Bethesda, MD; and Rhône-Poulenc Rorer, Collegeville, PA (now Aventis Pharma). References AB BIODISK North America Inc. (1997). Etest MIC determination of antibiotics package insert. Piscataway, NJ: AB BIODISK North America Inc. Archibald, L., Phillips, L., Monnet, D., McGowan J. E., Jr., Tenover, F., & Gaynes, R. (1997). Antimicrobial resistance in isolates from inpatients and outpatients in the United States: the increasing importance of the intensive care unit. Clin Infect Dis, 24, Biedenbach, D. J., & Jones, R. N. (1995). Interpretive errors using an automated system for the susceptibility testing of imipenem and aztreonam. Diagn Microbiol Infect Dis, 21, Carmeli, Y., Eichelberger, K., Soja, D., Dakos, J., Venkataraman, L., DeGirolami, P., & Samore, M. (1998). Failure of quality control measures to prevent reporting of false resistance to imipenem, resulting in a pseudo-outbreak of imipenem-resistant Pseudomonas aeruginosa. J Clin Microbiol, 36, Cercenado, E., Unal, S., Eliopoulos, C. T., Rubin, L. G., Isenberg, H. D., Moellering R. C., Jr., & Eliopoulos, G. M. (1996). Characterization of vancomycin resistance in Enterococcus durans. J Antimicrob Chemother, 36, Clark, N. C., Cooksey, R. C., Hill, B. C., Swenson, J. M., & Tenover, F. C. (1993). Characterization of glycopeptide-resistant enterococci from U.S. hospitals. Antimicrob Agents Chemother, 37, Doern, G. V., Brueggemann, A. B., Pfaller, M. A., & Jones, R. N. (1999). Assessment of laboratory performance with Streptococcus pneumoniae antimicrobial susceptibility testing in the United States: a report from the College of American Pathologists Microbiology Proficiency Survey Program. Arch Pathol Lab Med, 123, Facklam, R. R., Sahm, D. F., & Teixeira, L. M. (1999). Enterococcus. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, & R. H. Yolken (Eds.), Manual of Clinical Microbiology (pp ). Washington, D.C.: American Society for Microbiology. Farmer, J. J. (1999). Enterobacteriaceae: Introduction and Identification. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, & R. H. & Yolken (Eds.), Manual of Clinical Microbiology (pp ).Washington, D.C.: American Society for Microbiology. Farmer, J. J., Asbury, M. A., Hickman, F. W., & Brenner, D. J., the Enterobacteriaceae Study Group. (1980). Enterobacter sakazakii: a new species of Enterobacteriaceae isolated from clinical specimens. Int J Syst Bacteriol, 30, Fridkin, S. K., Steward, C. D., Edwards, J. R., Pryor, E. R., McGowan J. E., Jr., Archibald, L. K., Gaynes, R. P., & Tenover, F. C., Project Intensive Care Antimicrobial Resistance Epidemiology Hospitals. (1999). Surveillance of antimicrobial use and antimicrobial resistance in U.S. hospitals: Project ICARE Phase 2. Clin Infect Dis, 29, Grist, R. (1992). External factors affecting imipenem performance in dried microdilution MIC plates [letter]. J Clin Microbiol, 30, Jones, R. N., Marshall, S. A., Pfaller, M. A., Wilke, W. W., Hollis, R. J., Erwin, M. E., Edmond, M. B., Wenzel, R. P., & the SCOPE Hospital Study Group. (1997a). Nosocomial enterococcal blood stream infections in the SCOPE program: antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy. Diagn Microbiol Infect Dis, 29,
9 C.D. Steward et al. / Diagnostic Microbiology and Infectious Disease 38 (2000) Jones, R. N., Marshall, S. A., & Zerva, L. (1997b). Critical evaluation of the Vitek GNS F6 card results compared to standardized, reference susceptibility test methods. Diagn Microbiol Infect Dis, 28, Mabilat, C., & Goussard, S. (1993). PCR detection and identification of genes for extended-spectrum -lactamases. In D. H. Persing, T. F. Smith, F. C. Tenover, & T. J. White (Eds.), Diagnostic Molecular Microbiology: Principles and Applications (pp ). Washington, D.C.: American Society for Microbiology. National Committee for Clinical Laboratory Standards. (1997b). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Fourth edition. NCCLS approved standard M7 A4. Wayne, PA: National Committee for Clinical Laboratory Standards. National Committee for Clinical Laboratory Standards. (1997a). Performance standards for antimicrobial disk susceptibility tests. Sixth edition. NCCLS approved standard M2 A6. Wayne, PA: National Committee for Clinical Laboratory Standards. National Committee for Clinical Laboratory Standards. (1998). Performance standards for antimicrobial susceptibility testing. NCCLS approved standard M100 S8. Wayne, PA: National Committee for Clinical Laboratory Standards. National Committee for Clinical Laboratory Standards. (1999). Performance standards for antimicrobial susceptibility testing. NCCLS approved standard M100 S9. Wayne, PA: National Committee for Clinical Laboratory Standards. O Rourke, E. J., Lambert, K. G., Parsonnet, K. C., Macone, A. B., & Goldmann, D. A. (1991). False resistance to imipenem with a microdilution susceptibility testing system. J Clin Microbiol, 29, Pfaller, M. A., Korten, V., Jones, R. N., Doern, G. V., & Turkish Antimicrobial Resistance Study Group. (1999). Multicenter evaluation of the antimicrobial activity for seven broad-spectrum -lactams in Turkey using the Etest method. Diagn Microbiol Infect Dis, 35, Rasheed, J. K., Jay, C., Metchock, B., Berkowitz, F., Weigel, L., Crellin, J., Steward, C., Hill, B., Medeiros, A. A., & Tenover, F. C. (1997). Evolution of extended-spectrum -lactam resistance (SHV-8) in a strain of Escherichia coli during multiple episodes of bacteremia. Antimicrob Agents Chemother, 41, Rosenberg, J., Tenover, F. C., Wong, J., Jarvis, W., & Vugia, D. J. (1997). Are clinical laboratories in California accurately reporting vancomycin-resistant enterococci? J Clin Microbiol, 35, Singer, D. A., Jochimsen, E. M., Gielerak, P., & Jarvis, W. R. (1996). Pseudo-outbreak of Enterococcus durans infections and colonization associated with introduction of an automated identification system software update. J Clin Microbiol, 34, Steward, C. D., McGowan J. E., Jr., Tenover, F. C., Fridkin, S. K., Gaynes, R. P., & Project ICARE Hospitals. (1998). Multicenter study of susceptibility of imipenem demonstrates that testing problems persist, abstr. 769, IDSA, 36th Annual Meeting, Clin Infect Dis, 27, Tenover, F. C., Mohammed, M. J., Gorton, T. S., & Dembek, Z. F. (1999). Detection and reporting of organisms producing extended-spectrum -lactamases: survey of laboratories in Connecticut. J Clin Microbiol, 37, Tenover, F. C., Tokars, J., Swenson, J., Paul, S., Spitalny, K., & Jarvis, W. (1993). Ability of clinical laboratories to detect antimicrobial agentresistant enterococci. J Clin Microbiol, 31, Vannuffel, P., Gigi, J., Ezzedine, H., Vandercam, B., Delmee, M., Wauters, G., & Gala, J. L. (1995). Specific detection of methicillin-resistant Staphylococcus species by multiplex PCR. J Clin Microbiol, 33, White, R. L., Kays, M. B., Friedrich, L. V., Brown, E. W., & Koonce, J. R. (1991). Pseudoresistance of Pseudomonas aeruginosa resulting from degradation of imipenem in an automated susceptibility testing system with predried panels. J Clin Microbiol, 29, Yigit, H., Steward, C. D., Biddle, J. W., & Tenover, F. C. (1999). Characterization of -lactamases and porin changes in carbapenem-resistant isolates of Klebsiella pneumoniae and Serratia marcescens, abstr. A-61 In Abstracts of the, 99th American Society for Microbiology General Meeting, Washington, D.C.: American Society for Microbiology, pp13.
Understanding the Hospital Antibiogram
Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital
More informationBackground and Plan of Analysis
ENTEROCOCCI Background and Plan of Analysis UR-11 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony count, to perform the identification
More informationESBL Producers An Increasing Problem: An Overview Of An Underrated Threat
ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat Hicham Ezzat Professor of Microbiology and Immunology Cairo University Introduction 1 Since the 1980s there have been dramatic
More informationa. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.
AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony
More informationJasmine M. Chaitram, 1,2 * Laura A. Jevitt, 1,2 Sara Lary, 1,2 Fred C. Tenover, 1,2 and The WHO Antimicrobial Resistance Group 3,4
JOURNAL OF CLINICAL MICROBIOLOGY, June 2003, p. 2372 2377 Vol. 41, No. 6 0095-1137/03/$08.00 0 DOI: 10.1128/JCM.41.6.2372 2377.2003 The World Health Organization s External Quality Assurance System Proficiency
More informationEvaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals
J Vet Diagn Invest :164 168 (1998) Evaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals Susannah K. Hubert, Phouc Dinh Nguyen, Robert D. Walker Abstract.
More informationEducating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges
Educating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges Janet Hindler, MCLS MT(ASCP) UCLA Medical Center jhindler@ucla.edu also working as a consultant with the Association
More informationOriginal Article. Ratri Hortiwakul, M.Sc.*, Pantip Chayakul, M.D.*, Natnicha Ingviya, B.Sc.**
Original Article In Vitro Activity of Cefminox and Other β-lactam Antibiotics Against Clinical Isolates of Extended- Spectrum-β-lactamase-Producing Klebsiella pneumoniae and Escherichia coli Ratri Hortiwakul,
More informationMICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC
MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical
More informationTHE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS
THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS Stefanie Desmet University Hospitals Leuven Laboratory medicine microbiology stefanie.desmet@uzleuven.be
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIII NUMBER 1 July 2008 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell, SM (ASCP), Marti Roe SM (ASCP), Ann-Christine Nyquist MD, MSPH Are the bugs winning? The 2007
More informationAre Clinical Laboratories in California Accurately Reporting Vancomycin-Resistant Enterococci?
JOURNAL OF CLINICAL ROBIOLOGY, Oct. 1997, p. 2526 2530 Vol. 35, No. 10 0095-1137/97/$04.00 0 Copyright 1997, American Society for Microbiology Are Clinical Laboratories in California Accurately Reporting
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The
More informationMethod Preferences and Test Accuracy of Antimicrobial Susceptibility Testing
Method Preferences and Test Accuracy of Antimicrobial Susceptibility Testing Updates From the College of American Pathologists Microbiology Surveys Program (2000) Ronald N. Jones, MD; for the College of
More informationAPPENDIX III - DOUBLE DISK TEST FOR ESBL
Policy # MI\ANTI\04\03\v03 Page 1 of 5 Section: Antimicrobial Susceptibility Testing Manual Subject Title: Appendix III - Double Disk Test for ESBL Issued by: LABORATORY MANAGER Original Date: January
More informationDefining Extended Spectrum b-lactamases: Implications of Minimum Inhibitory Concentration- Based Screening Versus Clavulanate Confirmation Testing
Infect Dis Ther (2015) 4:513 518 DOI 10.1007/s40121-015-0094-6 BRIEF REPORT Defining Extended Spectrum b-lactamases: Implications of Minimum Inhibitory Concentration- Based Screening Versus Clavulanate
More informationConcise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
More informationSusceptibility Testing and Resistance Phenotypes Detection in Bacterial Pathogens Using the VITEK 2 System
Polish Journal of Microbiology 2005, Vol. 54, No 4, 311 316 Susceptibility Testing and Resistance Phenotypes Detection in Bacterial Pathogens Using the VITEK 2 System EL BIETA STEFANIUK*, AGNIESZKA MRÓWKA
More informationTel: Fax:
CONCISE COMMUNICATION Bactericidal activity and synergy studies of BAL,a novel pyrrolidinone--ylidenemethyl cephem,tested against streptococci, enterococci and methicillin-resistant staphylococci L. M.
More informationESCMID Online Lecture Library. by author
Quality Assurance of antimicrobial susceptibility testing Derek Brown EUCAST Scientific Secretary ESCMID Postgraduate Education Course, Linz, 17 September 2014 Quality Assurance The total process by which
More informationIntrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
More informationAntimicrobial Susceptibility Testing: Advanced Course
Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to
More informationService Delivery and Safety Department World Health Organization, Headquarters
Service Delivery and Safety Department World Health Organization, Headquarters WHO global (laboratory-based) survey on multidrug-resistant organisms (MDROs) in health care PROJECT SUMMARY Given the important
More informationEARS Net Report, Quarter
EARS Net Report, Quarter 4 213 March 214 Key Points for 213* Escherichia coli: The proportion of patients with invasive infections caused by E. coli producing extended spectrum β lactamases (ESBLs) increased
More informationAntimicrobial Stewardship Strategy: Antibiograms
Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide
More informationOriginal Articles. K A M S W Gunarathne 1, M Akbar 2, K Karunarathne 3, JRS de Silva 4. Sri Lanka Journal of Child Health, 2011; 40(4):
Original Articles Analysis of blood/tracheal culture results to assess common pathogens and pattern of antibiotic resistance at medical intensive care unit, Lady Ridgeway Hospital for Children K A M S
More informationQuality assurance of antimicrobial susceptibility testing
Quality assurance of antimicrobial susceptibility testing Derek Brown Routine quality control Repeated testing of controls in parallel with tests to ensure that the test system is performing reproducibly
More informationPerformance Information. Vet use only
Performance Information Vet use only Performance of plates read manually was measured in three sites. Each centre tested Enterobacteriaceae, streptococci, staphylococci and pseudomonas-like organisms.
More informationAgent-Resistant Enterococci
JOURNAL OF CLINICAL MICROBIOLOGY, July 1993, p. 1695-1699 0095-1137/93/071695-05$02.00/0 Copyright 1993, American Society for Microbiology Vol. 31, No. 7 Ability of Clinical Laboratories To Detect Antimicrobial
More informationFlorida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC
Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC 11/20/2014 1 To describe carbapenem-resistant Enterobacteriaceae. To identify laboratory detection standards for carbapenem-resistant
More information2016 Antibiotic Susceptibility Report
Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates
More informationThe Basics: Using CLSI Antimicrobial Susceptibility Testing Standards
The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards Janet A. Hindler, MCLS, MT(ASCP) UCLA Health System Los Angeles, California, USA jhindler@ucla.edu 1 Learning Objectives Describe information
More informationOverview of Nosocomial Infections Caused by Gram-Negative Bacilli
HEALTHCARE EPIDEMIOLOGY Robert A. Weinstein, Section Editor INVITED ARTICLE Overview of Nosocomial Infections Caused by Gram-Negative Bacilli Robert Gaynes, Jonathan R. Edwards, and the National Nosocomial
More informationNew Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs
New Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs Patrick R. Murray, PhD Senior Director, WW Scientific Affairs 2017 BD. BD, the BD Logo and all other trademarks
More informationGuidelines for Laboratory Verification of Performance of the FilmArray BCID System
Guidelines for Laboratory Verification of Performance of the FilmArray BCID System Purpose The Clinical Laboratory Improvement Amendments (CLIA), passed in 1988, establishes quality standards for all laboratory
More information2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine
2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01
More informationAntibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting
Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria
More information2015 Antibiotic Susceptibility Report
Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens
More informationC&W Three-Year Cumulative Antibiogram January 2013 December 2015
C&W Three-Year Cumulative Antibiogram January 213 December 215 Division of Microbiology, Virology & Infection Control Department of Pathology & Laboratory Medicine Contents Comments and Limitations...
More informationHelen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory
METHODS USED IN NEW ZEALAND DIAGNOSTIC LABORATORIES TO IDENTIFY AND REPORT EXTENDED-SPECTRUM β-lactamase- PRODUCING ENTEROBACTERIACEAE by Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXVII NUMBER 6 July 2012 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine B. Dowell SM, MLS (ASCP); Sarah K. Parker, MD; James K. Todd, MD Each year the Children s Hospital Colorado
More informationEXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING
EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING CHN61: EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING 1.1 Introduction A common mechanism of bacterial resistance to beta-lactam antibiotics is the production
More informationENTEROCOCCI. April Abbott Deaconess Health System Evansville, IN
ENTEROCOCCI April Abbott Deaconess Health System Evansville, IN OBJECTIVES Discuss basic antimicrobial susceptibility principles and resistance mechanisms for Enterococcus Describe issues surrounding AST
More informationagainst Clinical Isolates of Gram-Positive Bacteria
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 366-370 Vol. 37, No. 0066-0/93/00366-05$0.00/0 Copyright 993, American Society for Microbiology In Vitro Activity of CP-99,9, a New Fluoroquinolone,
More informationHelp with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST
Help with moving disc diffusion methods from BSAC to EUCAST This document sets out the main differences between the BSAC and EUCAST disc diffusion methods with specific emphasis on preparation prior to
More informationMercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016
Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate
More informationPrevalence of Metallo-Beta-Lactamase Producing Pseudomonas aeruginosa and its antibiogram in a tertiary care centre
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 4 Number 9 (2015) pp. 952-956 http://www.ijcmas.com Original Research Article Prevalence of Metallo-Beta-Lactamase
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXXII NUMBER 6 September 2017 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Stacey Hamilton MT SM (ASCP), Samuel Dominguez MD PhD, Sarah Parker MD, and
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIX NUMBER 3 November 2014 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Marti Roe SM MLS (ASCP), Sarah Parker MD, Jason Child PharmD, and Samuel R.
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/26062
More informationOver the past several decades, the frequency of. Resistance Patterns Among Nosocomial Pathogens* Trends Over the Past Few Years. Ronald N.
Resistance Patterns Among Nosocomial Pathogens* Trends Over the Past Few Years Ronald N. Jones, MD Multiple surveillance studies have demonstrated that resistance among prevalent pathogens is increasing
More informationBACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016)
BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016) VA Palo Alto Health Care System April 14, 2017 Trisha Nakasone, PharmD, Pharmacy Service Russell Ryono, PharmD, Public Health Surveillance
More informationAntimicrobial Resistance Strains
Antimicrobial Resistance Strains Microbiologics offers a wide range of strains with characterized antimicrobial resistance mechanisms including: Extended-Spectrum β-lactamases (ESBLs) Carbapenamases Vancomycin-Resistant
More informationAntimicrobial Susceptibility Testing: The Basics
Antimicrobial Susceptibility Testing: The Basics Susan E. Sharp, Ph.D., DABMM, FAAM Director, Airport Way Regional Laboratory Director, Regional Microbiology and Molecular Infectious Diseases Laboratories
More informationMili Rani Saha and Sanya Tahmina Jhora. Department of Microbiology, Sir Salimullah Medical College, Mitford, Dhaka, Bangladesh
Detection of extended spectrum beta-lactamase producing Gram-negative organisms: hospital prevalence and comparison of double disc synergy and E-test methods Mili Rani Saha and Sanya Tahmina Jhora Original
More informationTaiwan Surveillance of Antimicrobial Resistance (TSAR)
Taiwan Surveillance of Antimicrobial Resistance (TSAR) 2009 MIRL Symposium July 17, 2009 Tsai-Ling Yang Lauderdale ( ) Microbial Infections Reference Laboratory (MIRL) Division of Infectious Diseases,
More information/01/$ DOI: /JCM Copyright 2001, American Society for Microbiology. All Rights Reserved.
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 2001, p. 241 250 Vol. 39, No. 1 0095-1137/01/$04.00 0 DOI: 10.1128/JCM.39.1.241 250.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved. Ability
More informationRCH antibiotic susceptibility data
RCH antibiotic susceptibility data The following represent RCH antibiotic susceptibility data from 2008. This data is used to inform antibiotic guidelines used at RCH. The data includes all microbiological
More informationINFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER
INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER University of Minnesota Health University of Minnesota Medical Center University of Minnesota Masonic Children s Hospital May 2017 Printed herein are
More informationWhat s new in EUCAST methods?
What s new in EUCAST methods? Derek Brown EUCAST Scientific Secretary Interactive question 1 MIC determination MH-F broth for broth microdilution testing of fastidious microorganisms Gradient MIC tests
More informationMICHAEL A. PFALLER,* RONALD N. JONES, GARY V. DOERN, KARI KUGLER, AND THE SENTRY PARTICIPANTS GROUP
ANTIROBIAL AGENTS AND CHEMOTHERAPY, July 1998, p. 1762 1770 Vol. 42, No. 7 0066-4804/98/$04.00 0 Copyright 1998, American Society for Microbiology. All Rights Reserved. Bacterial Pathogens Isolated from
More informationEDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update
EDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain
More informationIn Vitro Antimicrobial Activity of CP-99,219, a Novel Azabicyclo-Naphthyridone
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 39-353 0066-0/93/0039-05$0.00/0 Copyright 993, American Society for Microbiology Vol. 37, No. In Vitro Antimicrobial Activity of, a Novel Azabicyclo-Naphthyridone
More informationجداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی
جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی ویرایش دوم بر اساس ed., 2017 CLSI M100 27 th تابستان ۶۹۳۱ تهیه
More informationAntimicrobial Resistance Surveillance from sentinel public hospitals, South Africa, 2013
Antimicrobial Resistance Surveillance from sentinel public s, South Africa, 213 Authors: Olga Perovic 1,2, Melony Fortuin-de Smidt 1, and Verushka Chetty 1 1 National Institute for Communicable Diseases
More informationEUCAST Subcommitee for Detection of Resistance Mechanisms (ESDReM)
EUCAST Subcommitee for Detection of Resistance Mechanisms (ESDReM) Christian G. Giske, MD/PhD Chairman of ESDReM Karolinska University Hospital and EUCAST ECCMID, 22 maj 2013 The background Guidance on
More informationSuggestions for appropriate agents to include in routine antimicrobial susceptibility testing
Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory
More informationChemotherapy of bacterial infections. Part II. Mechanisms of Resistance. evolution of antimicrobial resistance
Chemotherapy of bacterial infections. Part II. Mechanisms of Resistance evolution of antimicrobial resistance Mechanism of bacterial genetic variability Point mutations may occur in a nucleotide base pair,
More informationTwo (II) Upon signature
Page 1/5 SCREENING FOR ANTIBIOTIC RESISTANT ORGANISMS (AROS) IN ACUTE CARE AND LONG TERM CARE Infection Prevention and Control IPC 050 Issuing Authority (sign & date) Office of Administrative Responsibility
More informationSystems Approach to Improving Antimicrobial Susceptibility Testing in Clinical Laboratories in the United States
JOURNAL OF CLINICAL MICROBIOLOGY, July 2007, p. 2230 2234 Vol. 45, No. 7 0095-1137/07/$08.00 0 doi:10.1128/jcm.00184-07 Copyright 2007, American Society for Microbiology. All Rights Reserved. Systems Approach
More informationPrevalence of Extended-spectrum β-lactamase Producing Enterobacteriaceae Strains in Latvia
Prevalence of Extended-spectrum β-lactamase Producing Enterobacteriaceae Strains in Latvia Ruta Paberza 1, Solvita Selderiņa 1, Sandra Leja 1, Jelena Storoženko 1, Lilija Lužbinska 1, Aija Žileviča 2*
More informationEDUCATIONAL COMMENTARY CURRENT METHODS IN ANTIMICROBIAL SUSCEPTIBILITY TESTING
Commentary provided by: Linsey Donner, MPH, CPH, MLS (ASCP) CM Assistant Professor, Microbiology and Serology College of Allied Health Professions, Division of Medical Laboratory Science University of
More informationUse of the National Committee for Clinical Laboratory Standards Guidelines for Disk Diffusion Susceptibility Testing in New York State Laboratories
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 2000, p. 3341 3348 Vol. 38, No. 9 0095-1137/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. Use of the National Committee for
More informationOriginal Article. Suthan Srisangkaew, M.D. Malai Vorachit, D.Sc.
Original Article Vol. 21 No.1 The optimum agent for ESBL screening and confirmatory tests:- Srisangkaew S & Vorachit M. 1 The Optimum Agent for Screening and Confirmatory Tests for Extended-Spectrum Beta-Lactamases
More informationCAP Laboratory Improvement Programs. Performance Accuracy of Antibacterial and Antifungal Susceptibility Test Methods
CAP Laboratory Improvement Programs Performance Accuracy of Antibacterial and Antifungal usceptibility Test Methods Report From the College of American Pathologists Microbiology urveys Program (001 003)
More informationEvaluation of the BIOGRAM Antimicrobial Susceptibility Test System
JOURNAL OF CLINICAL MICROBIOLOGY, Nov. 1985, p. 793-798 0095-1137/85/110793-06$02.00/0 Copyright 1985, American Society for Microbiology Vol. 22, No. 5 Evaluation of the BIOGRAM Antimicrobial Susceptibility
More informationKey words: Campylobacter, diarrhea, MIC, drug resistance, erythromycin
Key words: Campylobacter, diarrhea, MIC, drug resistance, erythromycin Table 1 Detection rate of Campylobacter from stool samples taken from sporadic diarrheic patients Table 2 Detection rates of Campylobacter
More informationUNDERSTANDING YOUR DATA: THE ANTIBIOGRAM
UNDERSTANDING YOUR DATA: THE ANTIBIOGRAM April Abbott, PhD, D(ABMM) Deaconess Health System Evansville, IN April.Abbott@Deaconess.com Special thanks to Dr. Shelley Miller for UCLA data WHAT WE WILL COVER
More informationPROTOCOL for serotyping and antimicrobial susceptibility testing of Salmonella test strains
PROTOCOL for serotyping and antimicrobial susceptibility testing of Salmonella test strains 1 INTRODUCTION... 1 2 OBJECTIVES... 2 3 OUTLINE OF THE EQAS 2017... 2 3.1 Shipping, receipt and storage of strains...
More informationOriginal Article. Hossein Khalili a*, Rasool Soltani b, Sorrosh Negahban c, Alireza Abdollahi d and Keirollah Gholami e.
Iranian Journal of Pharmaceutical Research (22), (2): 559-563 Received: January 2 Accepted: June 2 Copyright 22 by School of Pharmacy Shaheed Beheshti University of Medical Sciences and Health Services
More information2 0 hr. 2 hr. 4 hr. 8 hr. 10 hr. 12 hr.14 hr. 16 hr. 18 hr. 20 hr. 22 hr. 24 hr. (time)
Key words I μ μ μ μ μ μ μ μ μ μ μ μ μ μ II Fig. 1. Microdilution plate. The dilution step of the antimicrobial agent is prepared in the -well microplate. Serial twofold dilution were prepared according
More informationSUPPLEMENT ARTICLE. S114 CID 2001:32 (Suppl 2) Diekema et al.
SUPPLEMENT ARTICLE Survey of Infections Due to Staphylococcus Species: Frequency of Occurrence and Antimicrobial Susceptibility of Isolates Collected in the United States, Canada, Latin America, Europe,
More informationVersion 1.01 (01/10/2016)
CHN58: ANTIMICROBIAL SUSCEPTIBILITY TESTING (CLSI) 1.0 PURPOSE / INTRODUCTION: 1.1 Introduction Antimicrobial susceptibility tests are performed in order to determine whether a pathogen is likely to be
More information2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services
2015 Antibiogram Red Deer Regional Hospital Central Zone Alberta Health Services Introduction. This antibiogram is a cumulative report of the antimicrobial susceptibility rates of common microbial pathogens
More informationReassessment of the "Class" Concept of Disk Susceptibility Testing
Reassessment of the "Class" Concept of Disk Susceptibility Testing Disks versus Minimal Inhibitory Concentrations with Eleven Cephalosporins ARTHUR L. BARRY, PH.D., CLYDE THORNSBERRY, PH.D., RONALD N.
More informationCompliance of manufacturers of AST materials and devices with EUCAST guidelines
Compliance of manufacturers of AST materials and devices with EUCAST guidelines Data are based on questionnaires to manufacturers of materials and devices for antimicrobial susceptibility testing. The
More informationDetection and Quantitation of the Etiologic Agents of Ventilator Associated Pneumonia in Endotracheal Tube Aspirates From Patients in Iran
Letter to the Editor Detection and Quantitation of the Etiologic Agents of Ventilator Associated Pneumonia in Endotracheal Tube Aspirates From Patients in Iran Mohammad Rahbar, PhD; Massoud Hajia, PhD
More informationJanuary 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimal Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) roth dilution: cation-adjusted Mueller-Hinton
More informationCompliance of manufacturers of AST materials and devices with EUCAST guidelines
Compliance of manufacturers of AST materials and devices with EUCAST guidelines Data are based on questionnaires to manufacturers of materials and devices for antimicrobial susceptibility testing. The
More informationANTIMICROBIAL RESISTANCE SURVEILLANCE FROM SENTINEL PUBLIC HOSPITALS, SOUTH AFRICA, 2014
ANTIMICROBIAL RESISTANCE SURVEILLANCE FROM SENTINEL PUBLIC HOSPITALS, SOUTH AFRICA, 2014 Olga Perovic, 1,2 Verushka Chetty 1 & Samantha Iyaloo 1 1 National Institute for Communicable Diseases, NHLS 2 Department
More informationTigecycline susceptibility report from an Indian tertiary care hospital
Indian J Med Res 129, April 2009, pp 446-450 Tigecycline susceptibility report from an Indian tertiary care hospital Bijayini Behera, Anupam Das *, Purva Mathur, Arti Kapil *, Ravisekhar Gadepalli * &
More informationFinnzymes Oy. PathoProof Mastitis PCR Assay. Real time PCR based mastitis testing in milk monitoring programs
PathoProof TM Mastitis PCR Assay Mikko Koskinen, Ph.D. Director, Diagnostics, Finnzymes Oy Real time PCR based mastitis testing in milk monitoring programs PathoProof Mastitis PCR Assay Comparison of the
More informationALARMING RATES OF PREVALENCE OF ESBL PRODUCING E. COLI IN URINARY TRACT INFECTION CASES IN A TERTIARY CARE NEUROSPECIALITY HOSPITAL
ALARMING RATES OF PREVALENCE OF ESBL PRODUCING E. COLI IN URINARY TRACT INFECTION CASES IN A TERTIARY CARE NEUROSPECIALITY HOSPITAL Pearl. A Prabal*,Sourav Maiti Institute of Neurosciences, Kolkata, India
More informationThe Nuts and Bolts of Antibiograms in Long-Term Care Facilities
The Nuts and Bolts of Antibiograms in Long-Term Care Facilities J. Kristie Johnson, Ph.D., D(ABMM) Professor, Department of Pathology University of Maryland School of Medicine Director, Microbiology Laboratories
More informationReceived: February 29, 2008 Revised: July 22, 2008 Accepted: August 4, 2008
J Microbiol Immunol Infect. 29;42:317-323 In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections at a medical center
More informationMain objectives of the EURL EQAS s
EQAS Enterococci, Staphylococci and E. coli EURL workshop, April, 11 Lourdes García Migura Main objectives of the EURL EQAS s To improve the comparability of antimicrobial susceptibility testing (AST)
More informationDetection of Methicillin Resistant Strains of Staphylococcus aureus Using Phenotypic and Genotypic Methods in a Tertiary Care Hospital
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 7 (2017) pp. 4008-4014 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.607.415
More informationRoutine internal quality control as recommended by EUCAST Version 3.1, valid from
Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus
More informationAntimicrobial Cycling. Donald E Low University of Toronto
Antimicrobial Cycling Donald E Low University of Toronto Bad Bugs, No Drugs 1 The Antimicrobial Availability Task Force of the IDSA 1 identified as particularly problematic pathogens A. baumannii and
More information